William J. Heim
Yale University · 22 works · 13,238 citations · h-index 16
Top works
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
- Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
- Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
- Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer
- B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)
- Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation
- Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups
- A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A mid-atlantic oncology program study
- Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab
- Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer
- Detection of decreased proportion of lymphocytes forming rosettes with sheep erythrocytes at 29°C in the blood of cancer patients
- A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy
- Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study.
- Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery
- A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study.
- Changes in the patterns of patient therapy and multidisciplinary consultation in CHOP and in comparison hospitals.
- Carcinoma of the lung: Immunotherapy with intradermal BCG and allogeneic tumor cells
- A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3‐times‐daily regimen to treat patients with recurrent metastatic breast cancer
- Lung cancer symptoms with cetuximab/taxane/carboplatin in first-line advanced NSCLC: Analysis of the BMS099 trial